Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma.

Cancers (Basel) · 2020 · PMC7464656 · PMID 32824780

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

Accordingly, there was a borderline significant favorable survival outcome for BRAF mutant patients treated with ipilimumab and nivolumab in the first line setting, compared to BRAF WT; HR for OS was 0.5 (95% CI 0.22–1.13, p = 0.096) and HR for PFS was 0.53 (95% CI 0.27–1.03, p = 0.061). 3.4.7.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.